Startup profile · funding coverage
AminoChain funding, valuation and investors
Decentralized biobank network for user-owned health data across medical institutions.
Keep track of AminoChain
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Seed
$5M · 2024
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$5M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
seed
Investors in latest funding
Lead: Andreessen Horowitz
Overview
AminoChain builds a decentralized biobank network connecting hospitals and research institutions so patients can consent to share biospecimens and health data while retaining ownership rights. The protocol targets DeSci (decentralized science) use cases — collaborative research without centralized data silos. AminoChain raised a $5M seed round in 2024 led by a16z crypto, described as Andreessen Horowitz's first DeSci investment per The Block.
Why AminoChain is interesting
First a16z crypto DeSci investment — $5M seed for HIPAA-adjacent institutional biospecimen sharing on blockchain rails.
Product & use cases
AminoChain protocol enables institutions to publish biospecimen and dataset metadata on-chain with patient consent frameworks — researchers query availability and negotiate access while audit trails record provenance.
- Patients contributing biospecimens to research with transparent consent tracking
- Hospitals monetizing or sharing de-identified biobank assets via network effects
- Pharma R&D teams discovering cohorts across participating institutions
Key facts
- Seed (2024): $5M led by a16z crypto — first a16z DeSci investment per The Block
- Decentralized biobank network for institutional biospecimen sharing
Funding history (newest first)
Seed
2024 $5MSource: https://www.theblock.co/post/aminochain-a16z-desci-seed
Investors in our directory
Funds linked from AminoChain's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: a16z crypto DeSci branding as first investment attracts protocol developers and institutional pilots in underserved biobank interoperability niche.
Health data on blockchain faces HIPAA, IRB, and institutional inertia — real adoption slower than crypto narrative. AminoChain must prove hospital participation beyond seed announcement. DeSci first-mover label helps fundraising; clinical utility is the hurdle.
-
Traditional biobanks (UK Biobank, All of Us) incumbent
Centralized national biobanks; AminoChain decentralized coordination layer.
-
Datavant / health data networks adjacent
Off-chain health data linking; AminoChain web3-native provenance.
-
Other DeSci protocols direct
Competing blockchain research data projects.
Notable stories
- a16z crypto labeled AminoChain its first DeSci investment — decentralized science on blockchain for biobank coordination (The Block, 2024).
Industries
FAQs about AminoChain
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.